Search
forLearn
5 / 801 resultslearn PENTAVITIN®
learn enoxolone
learn vanillyl butyl ether
learn Betamethasone Valerate
Research
5 / 1000+ results
research CLINICAL EVALUATION OF HAIRBAC TABLET AND OIL IN THE MANAGEMENT OF DIFFUSE HAIR LOSS: AN OPEN CLINICAL STUDY
Hairbac tablet and oil significantly improve hair texture, density, and reduce hair loss without side effects.
research HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial
PrEP for HIV is less effective in transgender women mainly due to low adherence to the treatment.
research K ATP Channels and Cardiovascular Disease
K_ATP channel gene mutations are linked to heart diseases, but more research is needed to understand the connection and treatment potential.
research Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
research The Pharmacology of Regenerative Medicine
Regenerative pharmacology, which combines drugs with regenerative medicine, shows promise for repairing damaged body parts and needs more interdisciplinary research.
Community Join
5 / 1000+ resultscommunity My story (31 years old - male)
A 31-year-old male experienced hair thinning and initially used topical minoxidil, then switched to finasteride, which caused significant shedding. He later adopted a regimen of dutasteride, oral minoxidil, and anti-dandruff shampoo, leading to positive hair growth results, though he noted increased body hair as a side effect of oral minoxidil.
community Progress on oral min and dut I started on april 2024
OP reported significant hair regrowth using oral minoxidil 5mg, dutasteride 0.5mg, and dermastamping. Users discussed side effects, effectiveness of treatments, and debated dermastamp needle sizes.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
community Fluridil solution at Actifolic
Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.